Activated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse events

Sozio, Margaret S.Chalasani, Naga2016-10-252016-10-252014-11Sozio, M. S., & Chalasani, N. (2014). Activated Recombinant Factor VIIa should not be used in patients with refractory variceal bleeding – it is mostly ineffective, is expensive, and may rarely cause serious adverse events. Hepatology (Baltimore, Md.), 60(5), 1786–1788. http://doi.org/10.1002/hep.273631527-3350https://hdl.handle.net/1805/11237en-USPublisher Policyrecombinant Factor VIIarFVIIaBleedingCirrhosisActivated recombinant factor VIIa should not be used in patients with refractory variceal bleeding: it is mostly ineffective, is expensive, and may rarely cause serious adverse eventsArticle